Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

"State lawmakers have a month before they get back to work in the 2015 legislative session and already the debate over medical marijuana has gotten into the, ahem, weeds. State Rep. Allen Peake, R-Macon serves as co-chair of a joint legislative committee that has studied whether and how to legalize the drug for certain conditions, including seizures in children. Peake has revived a bill aimed at allowing cannabis oil made from marijuana plants for treatment of certain seizure disorders and other health problems. He is finalizing that proposal, pre-filed as House Bill 1 after a similar measure fell short last session. But another committee member, state Sen. Curt Thompson, D-Tucker, is proposing a competing bill that would allow vaporized, edible or smokable marijuana. Thompson also has filed a resolution, calling for a statewide referendum on whether to authorize recreational use of the drug. Confusion about the oil form versus a smokeable drug has prompted Peake, who said he does not support expanded use, to speak out. ""We believe that the medical cannabis oil –  very low in THC, that doesn’t have a psychoactive component to it, cannot get you high – is a better approach for our citizens,"" Peake said in a press conference before a committee meeting last week. Opponents of the oil have raised safety concerns. So PolitiFact Georgia decided to take a closer look at  Peake’s contention that the oil extracted from marijuana won’t get users high. First, a reminder that the federal government still classifies marijuana as a Schedule I substance, defined as ""the most dangerous"" drug ""with no currently accepted medical use."" Despite that designation, 23 states have legalized medical marijuana, allowing access to the drug for a variety of medical conditions. Another 11 states – including neighboring Alabama, Florida, North Carolina, South Carolina and Tennessee  – have enacted laws allowing cannabis oil products for medical reasons in limited situations. The key difference in allowing the oil, supporters say, is that it is high in cannabidiol and low in tetrahydrocannabinol. Both are compounds found in the marijuana plant that act on cell receptors that control neurotransmitters in the brain and the immune system from various organs, such as the spleen. Cannabidiol, known as CBD, is an antioxidant and not psychoactive. Tetrahydrocannabinol or THC is the long-known mind-altering part of pot. Cannabis oil is made from strains of marijuana already bred to be high in CBD and low in THC. For medical use, the oil is made with less than 3 percent THC and is orally ingested. Children’s doses tend to be at 1 percent THC, or lower. Studies are scarce on the medical benefits of such a product, given the Schedule I classification. But research does show that THC is what brings both it and CBD into the brain, where CBD’s antioxidant properties are thought to protect the brain. That evidence helped the federal Department of Health and Human Services earn a patent on medical marijuana in 2003. Anecdotally, parents of children with epilepsy and other seizure diseases back up the findings, reporting marked improvement from the cannabis oil. A London drug company, GW Pharmaceuticals, has created a drug out of highly purified CBD that has shown in preclinical studies that it potentially reduce seizures. The firm is waiting on final approval from Georgia Regents University and the federal Drug Enforcement Administration to begin clinical trials in Georgia with children who have severe seizure disorders. None of the existing studies or anecdotes from parents acknowledge or report any ""high"" from cannabis oil. Even the National Institute on Drug Abuse, while acknowledging the federal government does not see marijuana as medicine, reports that CBD as a ""non-psychoactive cannabinoid"" that may prove useful in treating epilepsy as well as some inflamation disorders and mental illnesses. In other words, while the medical use of cannabis oil can be debated given the limited number of medical and clinic studies, there is some common ground on the product. Marijuana remains officially a more dangerous drug than cocaine, according to the federal government. But the main component of the plant used to make cannabis oil doesn’t have the mind-altering, munchies-inducing effect associated with street use of the plant."
Unlike marijuana, medical cannabis oil cannot get you high.

This release makes no mention of the costs of the drugs compared in this study, even though the drugs have been in use for years and are widely available. Since the study is a comparison of various treatments for this form of cancer, it seems relevant to offer a cost comparison as well as a comparison of efficacy. It appears that the high dose methotrexate is given over a 24-hour period, presumably in the hospital, while the standard methotrexate is given as a single dose. Also, the high dose methotrexate is followed by leucovorin administration while the standard dose is not. According to the site GoodRx, the cost for methotrexate in low-dose (2.5 mg) pill form averages out to about $50 for a month’s supply. Newer, injectable variations of the drug cost upwards of $500 a month for the 25 mg dose. The release states that patients receiving high doses of the drug methotrexate “had a significantly better outcome, by 5 to 6 percent” than did patients receiving the current standard of care, which is gradually escalating doses of the drug. The release also explains that patients nine years old or younger who were also treated with a steroid called decadron (dexamethasone) for half as long as normal (14 versus 28 days) benefited from the treatment while patients 10 and older did not. We’re not sure of the meaning behind these results as portrayed in the release. Which outcome was better by 5 or 6 percent? The study has several. Does that mean the relapse rate was reduced or is it the event free survival that was better? It would be more meaningful to readers if the release had included the actual relapse and event free survival rates for each group analyzed in terms most people can understand. For example: “relapse rates were 5 percent lower in Group X compared to Group Y.” We’ll give this category a satisfactory rating largely due to the release including information that patients 10 and older receiving dexamethasone “were at much higher risk for a debilitating bone condition called osteonecrosis,” although we would have been happier if that greater risk would have been quantified. However, the published study explains that there were toxicity problems beyond that of dexamethasone and the release would have been stronger including that information as well. The release stated the study was randomized and controlled, and provides a broad overview of the study design, for which we give the release a borderline satisfactory under this criteria. However, these are the superficial results. On deeper delving into the study methodology, the statistical significances of the results were very close to not statistically significant. This is due to their planned interim stopping of the treatment and the fact that they were looking at multiple outcomes in multiple groups. This release doesn’t demonstrate disease-mongering. While the release does say that this clinical trial was run by the Children’s Oncology Group, which is funded by the National Cancer Institute and the National Institutes of Health, it makes no mention of possible conflicts of interest. Compounding that is the fact that the published study says, “Disclosures provided by the authors are available with this article at www.jco.org,” but that information is behind the journal’s paywall for most readers, so it’s unknown if there is, or is not, a conflict. It appears as though five of the authors (out of a total of about 20) have some conflicts of interest, mostly from several types of drug company payments. The release is comparing the efficacy of treatment regimens using different drugs so alternative treatments for B-acute lymphoblastic leukemia are noted. The release makes clear at the end that the treatment of this disease is improving thanks to refinement of the use of existing drug treatments, meaning that they are readily available for patient use. The release suggests the study findings could change the way childhood leukemia is treated. Modifying existing treatments to enhance a patient’s survival is certainly novel enough to warrant a release. There is no use of unjustifiable language in this release. However, the tone may be a bit overly optimistic given the study findings.
Relapses of childhood leukemia improve with high doses of common chemo drug

The 95-year-old Carter and his wife of more than 70 years, Rosalynn, attended services at the Maranatha Baptist Church in Plains on Sunday, news outlets reported. Parishioners also prayed for the Carters, who were nestled into front-row seats at the church where Carter famously has taught Sunday school. The nation’s oldest-ever ex-president underwent surgery last month at Emory University Hospital in Atlanta to relieve pressure on his brain caused by bleeding from a fall. Carter has faced several health issues in recent years. Earlier this month, he was treated at a hospital for a urinary tract infection. In October, he was hospitalized for a fall that fractured his pelvis and another fall in which he hit his head and required 14 stitches. A previous fall required he get hip surgery. In 2015, he was diagnosed with melanoma. After having parts of his liver removed and undergoing radiation, immunotherapy and treatment for brain lesions, he announced that he was cancer-free.

After brain surgery, Jimmy Carter returns to hometown church.